Toxoplasma gondii is an obligate intracellular parasitic protozoan which causes the disease toxoplasmosis. Infection with T. gondii is quite common in humans (as high as 60% of the population in the United States are seropositive) but is asymptomatic (90% of cases) in immunocompetent individuals (19) . By contrast, the disease represents a major health problem for immunocompromised individuals, such as AIDS patients and the unborn children of infected mothers (20, 23, 26) . Toxoplasmic encephalitis has become the most common cause of intracerebral mass lesions in AIDS patients and possibly the most commonly recognized opportunistic infection of the central nervous system (20, 23) . The frequency of congenital toxoplasmosis is as high as 1/1,000 live births (23) . Effects range in severity from asymptomatic to stillbirth, with the most common ailments being retinochoroiditis, cerebral calcifications, psychomotor or mental retardation, and severe brain damage (23) .
In spite of the tragic consequences of toxoplasmosis, the therapy for the disease has not changed in the last 25 years. The efficacy of the current therapy for toxoplasmosis (a combination of pyrimethamine and sulfadiazine) is limited, primarily by serious host toxicity and ineffectiveness against tissue cysts (20, 23, 26, 29) . Furthermore, as many as 50% of patients do not respond to therapy (20) . Other therapies, e.g., clindamycin or atovaquone, have met with limited success particularly in the long-term management of these patients. Therefore, it is imperative to search for more-efficacious and lesstoxic therapies for the treatment and long-term management of toxoplasmosis.
The rational design of a drug depends on the exploitation of fundamental biochemical or metabolic differences between pathogens and their host. Structure-activity relationship studies of T. gondii adenosine kinase (EC 2.7.1.20) demonstrated significant differences between the enzymes from Toxoplasma and those from their mammalian hosts in their substrate specificities (16) . Various 6-substituted 9-␤-D-ribofuranosylpurines were found to be among the best ligands that bind to T. gondii adenosine kinase (16) . This was quite unusual since the compounds were not known to be active ligands of adenosine kinase from other species. Among these 6-substituted 9-␤-Dribofuranosylpurines, nitrobenzylthioinosine {NBMPR; 6-[(4-nitrobenzyl)mercapto]-9-␤-D-ribofuranosylpurine} was shown to be phosphorylated to the nucleotide level by the T. gondii, but not the mammalian, adenosine kinase and exerted selective toxicity against T. gondii-infected cells (12, 13) .
NBMPR has been extensively investigated as an inhibitor of nucleoside transport in mammalian cells. However, none of these studies has shown that NBMPR is transported into or metabolized by mammalian cells. Furthermore, there is no direct evidence that T. gondii can transport NBMPR (4, 12, 13) . How NBMPR enters Toxoplasma-infected cells and subsequently the intracellular parasites is not known.
Transport studies on extracellular Toxoplasma identified two carriers that can transport purine nucleosides (4, 5, 25) . The first is a nonspecific nucleoside transporter (TgAT2) that seems to transport both purine and pyrimidine nucleosides (5). The second is an adenosine/purine nucleoside transporter (TgAT1), with ␤-D-adenosine being the preferred substrate (4). However, it is not known whether either of these two nucleoside carriers can transport NBMPR.
In the present study, we established that NBMPR is a permeant for the adenosine/purine nucleoside carrier(s) in T. gondii. Furthermore, we demonstrate that the Toxoplasma adenosine/purine nucleoside transporter(s) is different from mammalian equilibratory and concentrative transporters in that it is not stereospecifc. In contrast to mammalian cells, the parasite adenosine/purine nucleoside transporter(s) transports nonphysiological ␤-L-enantiomers of purine nucleosides (␤-Ladenosine, ␤-L-deoxyadenosine, and ␤-L-guanosine). Figure 1 shows the chemical structures of ␤-D-and ␤-L-adenosine.
MATERIALS AND METHODS

Chemicals and supplies
, and ␤-L-thymidine, were generously provided by ldenix Pharmaceuticals, Boston, Mass. Preformulated tetrabutyl ammonium phosphate buffer was purchased from Alltech Association, Inc., Deerfield, Ill. All other chemicals and compounds were obtained from Sigma Chemical Co., St. Louis, Mo., or Fisher Scientific, Pittsburgh, Pa.
Maintenance of T. gondii. The RH and TgAT Ϫ strains of T. gondii were propagated by intraperitoneal (i.p.) passage in female CD 1 mice (20 to 25 g). RH is a wild type strain and the TgAT Ϫ strain is a mutant deficient in the adenosine/purine nucleoside transporter(s) (4, 27) . Mice were injected i.p. with an inoculum (10 6 cells) of T. gondii contained in 0.2 ml of sterile phosphatebuffered saline (PBS), pH 7.2, and were sacrificed after 2 to 3 days by inhalation of ether. The parasites were harvested from the peritoneal cavity by injection, aspiration, and reinjection of 3 to 5 ml of PBS (two or three times). The peritoneal fluid was examined microscopically to determine the concentration of T. gondii and to ascertain the extent of contamination by host cells. Two-day transfers generally produce parasite preparations that contain very little contamination and have a viability of Ͼ95%.
Preparation of parasites. When T. gondii was used for in vitro incorporation studies, the procedure was performed aseptically and the parasites were washed and resuspended in RPMI 1640 medium (GIBCO BRL) containing 100 U of penicillin G/ml, 100 g of streptomycin sulfate/ml, and 3% fetal bovine serum (FBS; HyClone Laboratories, Logan, Utah).
Uptake of radiolabeled compounds in the presence and absence of other compounds. Uptake and incorporation of the radiolabeled compounds into the nucleoside and nucleotide pool of intracellular T. gondii were carried out in at least triplicate by using monolayers of human foreskin fibroblasts cultured for no more than 30 passages in RPMI 1640 and infected with T. gondii. Briefly, confluent cells (4 to 5 days of incubation) were cultured for 24 h in 24-well flat-bottom microtiter plates (ϳ5 ϫ 10 5 cells/ml/well) and incubated at 37°C in 5% CO 2 -95% air to allow the cells to attach. The medium was then removed, and the cells were infected with isolated T. gondii in medium with 3% FBS (one parasite per cell). After 1 h of incubation, the cultures were washed with 10% FBS medium to remove the extracellular parasites. FBS was maintained at a final concentration of 10%. The radiolabeled purine nucleosides were then added to cultures of the parasite-infected cells to give a final concentration of 10 M, in the presence and absence of competing nucleosides or nucleoside transport inhibitors at a final concentration of 100 M. After 4 h of incubation the fibroblasts were released from the wells by aspirating the medium; the cells were then washed three times with cold PBS and trypsinized by the addition of 200 l of trypsin-EDTA (2.5ϫ) to each well. One milliliter of 60% ice-cold methanol was added to each well, after which the cells were forced to break up by passing them through a 22-gauge needle. Each well's contents were then transferred into an Eppendorf tube, and the samples were stored at Ϫ20°C overnight. The samples were then spun down at 1,200 rpm for 10 min at 4°C. The supernatant was aspirated, air dried, and then reconstituted in 210 l of double-distilled water. The radioactivity in samples of 10 l was counted in scintillation vials containing 5 ml of Econo-Safe scintillation fluor (Research Products International Corp., Mount Prospect, Ill.) with an LS5801 (Beckman) scintillation counter. The remaining 200 l was stored at Ϫ20°C until analysis by highpressure liquid chromatography (HPLC).
HPLC analysis. The HPLC analysis of the nucleoside and nucleotide pool of the intracellular Toxoplasma was performed on two Hypersil C 18 reverse-phase (25-by 0.4-cm; octyldecyl saline, 5 m) columns (Jones Chromatography, Littleton, Colo.) tandemly connected to a computer-controlled Hewlett-Packard 1050 HPLC system with an autosampler, quaternary pump, and multiple-wavelength diode array base triple-channel UV monitor. A 100-l aliquot of the extract was injected. Elution was performed stepwise by using two mobile phases, 25 mM ammonium acetate in 5 mM preformulated tetrabutyl ammonium phosphate buffer, pH 7.0 (buffer A), and methanol (buffer B), and a multistage linear gradient. Elution started with buffer B at a gradient of 0 to 10% during the first 5 min and a constant flow rate of 0.8 ml/min. The elution flow was then increased to 1 ml/min, and the gradient of buffer B was increased from 10 to 15% at 40 min; it reached 25% at 45 min and 30% at 55 min and was maintained at 30% until 60 min. The radioactivity content of the eluent was quantitated by the use of an online 525TR Radiomatic Flo-One radiochromatography analyzer (Packard Instrument Company, Inc., Meriden, Conn.). Under these chromatographic conditions, the retention times of ␤-D-adenosine, ␤-L-adenosine, ␤-L-deoxyadenosine, AMP, ADP, ATP, NBMPR, and NBMPR 5Ј-monophosphate were about 25, 20, 30, 42, 47, 50, 68, and 56 min, respectively. Figure 2 shows that intracellular Toxoplasma parasites grown in human fibroblasts in culture were able to take up ␤-D-adenosine and NBMPR, as well as the nonphysiological purine nucleoside ␤-L-enantiomers, ␤-L-adenosine, ␤-L-deoxyadenosine, and ␤-L-guanosine; ␤-L-deoxyadenosine was the poorest substrate. Although the uptake of nonphysiological purine nucleoside enantiomers increased with time, HPLC analysis of the radioactive contents of parasites freed from infected cells indicated that, under these experimental conditions, none of the L-enantiomers were metabolized to their respective nucleotides by the intracellular parasites. On the Competition studies were performed in an effort to determine whether NBMPR and the unnatural purine ␤-L-enantiomers are transported into intracellular Toxoplasma and Toxoplasma-infected cells by the same nucleoside carrier(s) that transports ␤-D-adenosine. Figure 3 shows that the uptake of NBMPR and ␤-L-adenosine was inhibited by ␤-D-adenosine in a dose-dependent manner. These results suggest that NBMPR and ␤-L-adenosine in intracellular Toxoplasma and Toxoplasma-infected cells are transported by the same carrier(s) that transports ␤-D-adenosine.
RESULTS AND DISCUSSION
The results in Table 1 further confirm that NBMPR, the purine ␤-L-enantiomers, and ␤-D-adenosine are transported by the same carrier(s). The uptake of ␤-D-adenosine was substantially inhibited by ␤-L-adenosine (46%), and the uptake of ␤-L-adenosine was inhibited by ␤-D-adenosine to the same extent. The uptake of ␤-D-adenosine and that of ␤-L-adenosine were also inhibited by ␤-L-deoxyadenosine (41 and 20%, respectively) and ␤-L-guanosine (57 and 43%, respectively). Likewise, NBMPR uptake was significantly affected by ␤-D-
, and ␤-L-guanosine (43%). In a like manner, NBMPR inhibited the uptake of ␤-D-adenosine (67%), ␤-L-adenosine (63%), ␤-L-deoxyadenosine (33%), and ␤-L-guanosine (46%).
By comparison, ␤-D-inosine and hypoxanthine were less effective in inhibiting the uptake of all nucleosides tested, and ␤-D-inosine uptake was not considerably affected by these nucleosides. Similar results were observed in free extracellular tachyzoites (25) . Transport of ␤-D-adenosine was somewhat inhibited by ␤-D-inosine. However, the transport of ␤-D-inosine was less affected by ␤-D-adenosine (25) .
Dipyridamole, an inhibitor of adenosine transport in Toxoplasma (4, 25) and mammalian cells (reference 13 and references therein) inhibited the uptake of ␤-D-adenosine (63%), ␤-L-adenosine (70%), ␤-L-deoxyadenosine (31%), ␤-L-guanosine (34%), and NBMPR (46%). In contrast, the effect of dipyridamole on the uptake of ␤-D-inosine (11%) was less pro- a T. gondii-infected fibroblast cells were incubated with the substrate (10 M) for 4 h in the presence or absence of the inhibitor (100 M). Each value is the mean from two experiments with three replicates each.
b ND, not determined.
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on September 8, 2017 by guest http://aac.asm.org/ nounced. Similar results for extracellular parasites were observed (25) . Previous studies (4, 5, 25) identified two purine nucleoside transporters in free extracellular T. gondii tachyzoites. The first, TgAT2, is a nonspecific nucleoside transporter that seems to transport both purine and pyrimidine nucleosides (5). The second, TgAT1, is an adenosine/purine nucleoside transporter; adenosine is the preferred substrate, but TgAT1 can also transport ␤-D-inosine (4). Genetic evidence indicates that TgAT1 is the sole relevant transporter of adenosine in T. gondii. Inactivation of the TgAT1 locus eliminates virtually all adenosine transport (4) .
The strong correspondence between the results from previous studies on extracellular free parasites (4, 25) and the present results on intracellular parasites suggests that purine nucleoside transport in intracellular parasites is essentially the same as that in free extracellular parasites. Therefore, it was proposed that both TgAT1 and TgAT2 are products of the same gene (5) .
To ascertain further that the transport of NBMPR and purine ␤-L-nucleosides into intracellular Toxoplasma and Toxoplasma-infected cells is mediated by the parasite adenosine/ purine nucleoside transporter(s), the uptake of NBMPR and purine ␤-L-nucleosides was studied in fibroblast cells infected with TgAT Ϫ , a Toxoplasma mutant which is deficient in adenosine/purine nucleoside transport (4) . Infection with the TgAT Ϫ Toxoplasma mutant reduced or abolished the uptake of NBMPR and purine ␤-L-nucleosides (data not shown). Thus, in contrast to infection with wild-type parasites (Fig. 2) , infection with the TgAT Ϫ Toxoplasma transport mutant did not change the characteristics of nucleoside transport in the host cells to enable the infected host cells to take up NBMPR and the purine ␤-L-nucleosides. These results demonstrate that the observed uptake of NBMPR and purine ␤-L-nucleosides by intracellular Toxoplasma and host cells infected with wild-type parasites (Fig. 2) is indeed mediated by the same adenosine/ purine nucleoside transporter(s) that transports the natural ␤-D-adenosine into extracellular parasites. Therefore, it appears that infection with T. gondii conferred the properties of the parasite's purine nucleoside transport on the parasitized cells and enabled these infected cells to transport purine nucleosides (e.g., NBMPR and ␤-L-nucleosides) that were not transported before infection. Similar results were reported for nucleoside transport in Plasmodium falciparum-infected human erythrocytes (15, 28) and Plasmodium yoelii-infected mouse erythrocytes (14) . Infection with malaria parasites induced the malaria nonstereospecific nucleoside transporter in the parasitized host cells (3) .
There is an ongoing debate on how parasitism confers the properties of parasite nucleoside transport on parasitized cells. There are at least four possible pathways for induced nucleoside transport to occur in the parasitized host cell. The first is via an equilibratory high-affinity adenosine transport system (15, 28) . The second is by way of a concentrative ion-dependent channel (17) . The third pathway proposed is through tubovesicular membranes, which are interconnected networks extending from the parasitophorous vacuolar membrane, where the parasites reside, to the periphery of the infected cell (18) . The fourth is a via a duct for the transport of macromolecules that bypasses the host cell membrane (22) . Recent studies on the characteristics of P. falciparum nucleoside transporter PfNT1 (3) ruled out all proposed pathways except the induction of an equilibratory high-affinity adenosine transport system. The present results strongly suggest that a similar situation may exist in T. gondii-infected cells. The change in the substrate specificity and stereospecificity of nucleoside transport in host cells resulting from infection with Toxoplasma is most likely due to the induction of the Toxoplasma nonstereospecific adenosine transporter(s), thereby conferring its properties on the nucleoside transport of the parasitized host cells. In agreement with this conclusion, previous studies on Toxoplasma-infected cells excluded the possibility that plasma membrane proteins of host cells might form membrane channels or transporters from the parasitophorous vacuole membrane that surrounds the parasites within the host cells (references 2 and 24 and references therein).
The previous (4, 12, 13, 25 ) and present results demonstrate that the adenosine/purine nucleoside transporter(s) in T. gondii, differs from the mammalian equilibratory and concentrative transporters in three notable characteristics. First, the parasite adenosine/purine nucleoside transporter(s) exhibits lack of stereospecificity, transporting both ␤-D-adenosine and ␤-Ladenosine as well as other ␤-L-enantiomers of purine nucleosides. Mammalian transporters, on the other hand, are stereospecific for the D-enantiomers. Second, unlike mammalian transporters, the Toxoplasma adenosine/purine nucleoside transporter(s) is not inhibited by NBMPR but rather by high concentrations of dipyridamole. Third, NBMPR appears to be a permeant for this carrier(s), as Toxoplasma transports and metabolizes NBMPR. In addition infection with T. gondii parasites induces the Toxoplasma adenosine/purine nucleoside transporter(s) in the parasitized host cells.
In conclusion, further studies on nucleoside transporters in Toxoplasma are likely to provide insight into the mechanisms of purine transport and salvage by T. gondii and facilitate the assessment of purine transporters as valid chemotherapeutic targets for the treatment of toxoplasmosis. An understanding of the mechanisms of transport and membrane function in parasites as well as the differences in their properties compared to those of their mammalian hosts may provide the foundation for rational antiparasite drug development. Indeed, differences in the properties of nucleoside transport between mammalian and parasitic cells were the basis of a combination therapy approach involving the use of a cytotoxic purine nucleoside analogue and host-protecting mammalian transport inhibitors (1, 6-11, 14, 15, 21) .
